Intravenous acetylcysteine for indications other than acetaminophen overdose

American Journal of Health-System Pharmacy

Volumn 70, Issue 17, 2013, Pages 1496-1501

  Bass, Stephanie ^a   Zook, Nathaniel ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ST LUKE S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDOTE; PARACETAMOL;

ACUTE LIVER FAILURE; ALCOHOL LIVER DISEASE; ANAPHYLAXIS; ARTICLE; CONTRAST INDUCED NEPHROPATHY; DISEASE SEVERITY; DRUG INDICATION; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; OVERALL SURVIVAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; VASODILATATION; ANIMAL; DRUG OVERDOSE; HEPATITIS, ALCOHOLIC; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE, ACUTE;

ACETAMINOPHEN; ACETYLCYSTEINE; ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIDOTES; DRUG OVERDOSE; HEPATITIS, ALCOHOLIC; HUMANS; LIVER FAILURE, ACUTE;

EID: 84899043136     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120645     Document Type: Article

References (31)

1. Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009; 80:265-9.
2. Harrison PM, Wendon JA, Gimson AE et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991; 324:1852-7.
3. Acetadote (acetylcysteine) prescribing information. Nashville, TN: Cumberland Pharmaceuticals; 2008 Dec.
4. Kanter MZ. Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning. Am J Health-Syst Pharm. 2006; 63:1821-7.
5. Yarema MC, Johnson DW, Berlin RJ et al. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2009; 54:606-14.
6. Sklar GE, Subramaniam M. Acetylcysteine treatment for non-acetaminopheninduced acute liver failure. Ann Pharmacother. 2004; 38:498-501.
7. Kortsalioudaki C, Taylor RM, Cheeseman P et al. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl. 2008; 14:25-30.
8. Mumtaz K, Azam Z, Hamid S et al. Role of N-acetylcysteine in adults with non-acetaminophen-induced liver failure in a center without the facility of liver transplantation. Hepatol Int. 2009; 3:563-70.
9. Lee WM, Hynan LS, Rossaro L et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009; 137:856-64.
10. Squires RH, Dhawan A, Alonso E et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013; 57:1542-9.
11. O'Shea RS, Dasarathy S, McCullough AJ et al. Alcoholic liver disease. Hepatology. 2010; 51:307-28.
12. Maddrey WC, Boitnott JK, Bedine MS et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978; 75:193-9.
13. Nguyen-Khac E, Thevenot T, Piquet MA et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011; 365:1781-9.
14. Colell A, Garcia-Ruiz C, Miranda M et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 1998; 115:1541-51.
15. Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999; 353:294-5.
16. Phillips M, Curtis H, Portmann B et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial. J Hepatol. 2006; 44:784-90.
17. Stewart S, Prince M, Bassendine M et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol. 2007; 47:277-83.
18. Moreno C, Langlet P, Hittelet A et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010; 53:1117-22.
19. Massicotte A. Contrast medium-induced nephropathy: strategies for prevention. Pharmacotherapy. 2008; 28:1140-50.
20. Shalansky SJ, Pate GE, Levin A et al. N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration. Heart. 2005; 91:997-9.
21. Tepel M, Van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000; 343:180-4.
22. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002; 40:298-303.
23. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol. 2002; 89:356-8.
24. Briguori C, Colombo A, Violante A et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004; 25:206-11.
25. Stacul F, Adam A, Becker CR et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006; 98:59K-77K.
26. Berwanger O, Cavalcanti AB, Sousa AG et al. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011; 124:1250-9.
27. Baker CS, Wragg A, Kumar S et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003; 41:2114-8.
28. Webb JG, Pate GE, Humphries KH et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004; 148:422-9.
29. Rashid ST, Salman M, Myint F et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004; 40:1136-41.
30. Carbonell N, Blasco M, Sanjuan R et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol. 2007; 115:57-62.
31. Marenzi G, Assanelli E, Marana I et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006; 354:2773-82.